Subjects n | Tumour type | Study | Regimen | Agents | Doses | Response rate % | |
Single-agent chemotherapy | |||||||
Bonomi [90] | 21 | T/TC | Phase II | Cisplatin | 50 mg·m−2 every 3 weeks | 10 | |
Highley [91] | 15 | T/TC | Retrosp | Ifosfamide | 1.5 g·m−2×5 days every 3 weeks | 46 | |
Loehrer [92] | 27 | T/TC | Phase II | Pemetrexed | 500 mg·m−2 every 3 weeks | 17 | |
Combination chemotherapy | |||||||
Fornasiero [93] | 32 | T | Retrosp | ADOC | Adriamycin | 40 mg·m−2 every 3 weeks | 85–92 |
Cisplatin | 50 mg·m−2 every 3 weeks | ||||||
Vincristin | 0.6 mg·m−2 every 3 weeks | ||||||
Cyclophosphamide | 700 mg·m−2 every 3 weeks | ||||||
Loehrer [94] | 30 | T/TC | Phase II | CAP | Cisplatin | 50 mg·m−2 every 3 weeks | 51 |
Adriamycin | 50 mg·m−2 every 3 weeks | ||||||
Cyclophosphamide | 500 mg·m−2 every 3 weeks | ||||||
Giaccone [95] | 16 | T | Phase II | PE | Cisplatin | 60 mg·m−2 every 3 weeks | 56–60 |
Etoposide | 120 mg·m−2×3 days every 3 weeks | ||||||
Loehrer [96] | 34 | T/TC | Phase II | VIP | Etoposide | 75 mg·m−2×4 days every 3 weeks | 32 |
Ifosfamide | 1.2 g·m−2×4 days every 3 weeks | ||||||
Cisplatin | 20 mg·m−2×4 days every 3 weeks | ||||||
Lemma [97] | 46 | T/TC | Phase II | Carbo-Px | Carboplatin | AUC 5 every 3 weeks | 43 |
Paclitaxel | 225 mg·m−2 every 3 weeks | ||||||
Palmieri [98] | 15 | T/TC | Phase II | CAP-GEM | Capecitabine | 650 mg·m−2 b.i.d.×14 days every 3 weeks | 40 |
Gemcitabine | 1000 mg·m−2×2 days every 3 weeks | ||||||
Okuma [99] | 9 | TC | Retrosp | Cisplatin-irinotecan | Cisplatin | 80 mg·m−2 every 4 weeks | 56 |
Irinotecan | 60 mg·m−2×3 days every 4 weeks |
T: thymoma; TC: thymic carcinoma; Retrosp: retrospective; ADOC: adriamycin, cisplatin, vincristine and cyclophosphamide; CAP: cyclophosphamide, doxorubicin and cisplatin; PE: platin and etoposide; VIP: etoposide, ifosfamide and cisplatin; Carbo-Px: carboplatin and paclitaxel; CAP-GEM: capecitabine and gemcitabine; AUC: area under the curve.